In this Issue
- Lykos Therapeutics Rebrands to Resilient Pharmaceuticals
- Pharma Pushes Back on Norway’s Off-Label Ketamine Decision
- AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics
- Psilocybin Rescheduling Petition Heads to HHS
- Sensorium Scores $25M Series A Extension to Take Kanna-Based Candidate Into Clinic
- Researchers Call Lykos’ MDMA Pricing Modelling “Problematic”
- Alabama Board of Medicine Issues Guidelines for Off-Label Ketamine in TRD
- FDA Approves PharmaTher’s Ketamine After Two CRLs
- Incannex Reports Positive Phase 2 Results for Psilocybin-Assisted Psychotherapy in GAD
- and more…
***
Lykos Therapeutics Rebrands to Resilient Pharmaceuticals
MDMA drug developer Lykos Therapeutics has changed its name to Resilient Pharmaceuticals, Inc., Psychedelic Alpha understands.
The move comes after British investor and philanthropist Sir Chris Hohn and Musk ally Antonio Gracias teamed up to inject fresh funding into the ailing company, which suffered an FDA rejection last Summer.
That $50M recapitalisation, which the company called a Series B, was quickly followed by the appointment of a new execs, including Mike Burke as CEO and Javier Muniz as CMO.
According to a story published in The Guardian today, Gracias told Doblin at Burning Man last year “that the FDA’s rejection wasn’t his fault”. Instead, he “blamed the company’s other leaders for the failure.”
“Let Lykos go bust and start again with a clean slate, Gracias advised,” the Guardian article continued.
“Resilient is an inspiring name”, Rick Doblin told us today, when he briefly had WiFi at Burning Man.
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
